About the Company

[Summary] 肿瘤免疫治疗领域创新抗体药物研发

非同(成都)生物科技有限公司是由诺奖团队人员发起的创新药物研发企业,于2017年11月在成都高新区注册成立。团队成员具有深厚的学术和产业背景,专注于肿瘤免疫治疗领域创新抗体药物研发。公司已建成1200平方米的包括分子生物学、细胞生物学、结构生物学、药物评价、蛋白质工程实验室,搭建了包括单克隆抗体筛选、抗体人源化、分子活性检测和优化、蛋白质生产和纯化、以及纳米抗体技术等一系列国际水准的核心技术平台。通过扎实的科研基础,公司已建立包括单克隆抗体、双特异性抗体和融合蛋白在内的近20个生物大分子药物产品管线。

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

非同生物 Financing History (2 rounds)

Manage
Pre-A
Capital Market Favor
Latest Financing Round
  • Date: ?
  • Amount: 数千万人民币
  • Investor: 境成投资

非同生物 honors, qualifications & industry associations

Tags are labelled based on keyword text matching analysis and may be related to the company. For reference only.

非同生物 Related Industry Tags

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 9,494.7367万(元)
Legal Representative: 李庆
Date Established:
Credit Code: 91510100MA6C6Y9793
Registered Address: 成都天府国际生物城(双流区慧谷东二路8号5栋1单元6楼601号)

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates